Lung cancer is the leading cause of cancer-related death in American adults. Treatment for advanced cases of lung cancer is challenging, and typically involves a combination of surgery, radiation, chemotherapy and immunotherapy. The majority of lung cancer drugs are administered systemically, leading to potential systemic toxicity, side effects, high cost of treatment, and patient compliance issues. Delivery by the inhalation route for this lung-focused disease is an ideal means to circumvent many of the drawbacks associated with lung cancer treatment. Particle engineering is critical to the success of any inhalation product. To learn more, please view our webinar slides.     
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center